Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Sam J Lubner"'
Autor:
Dustin A Deming, Molly E Maher, Alyssa A Leystra, Joseph P Grudzinski, Linda Clipson, Dawn M Albrecht, Mary Kay Washington, Kristina A Matkowskyj, Lance T Hall, Sam J Lubner, Jamey P Weichert, Richard B Halberg
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e109668 (2014)
The treatment of localized colorectal cancer (CRC) depends on resection of the primary tumor with adequate margins and sufficient lymph node sampling. A novel imaging agent that accumulates in CRCs and the associated lymph nodes is needed. Cellectar
Externí odkaz:
https://doaj.org/article/d90497f5ff9945f6b8b2860f54bd5187
Autor:
Gabriella Geiger, Lauren Kiel, Miki Horiguchi, Celia Martinez-Aceves, Kelly Meza, Briana Christophers, Priscilla Orellana, Maria Mora Pinzon, Sam J. Lubner, Narjust Florez
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background The percentage of physicians identifying as Latina has not improved despite improvements in recruitment of Latina medical students, suggesting barriers to retention and career advancement. Discriminatory experiences and mental hea
Externí odkaz:
https://doaj.org/article/472e5361c3834296a42f2640e1c88a92
Publikováno v:
Journal of Clinical Oncology. 40:2751-2762
Immunotherapy (IO) agents have led to significant improvements in patient outcomes across many tumor types. There have been great efforts to introduce immune checkpoint inhibitors into the treatment paradigm of esophagogastric cancers as well. A numb
Autor:
Shannon Stockton, Paul Catalano, Steven J Cohen, Barbara A Burtness, Edith P Mitchell, Efrat Dotan, Sam J Lubner, Pankaj Kumar, Mary F Mulcahy, George A Fisher, Theodore L Crandall, Al Benson
Publikováno v:
The Oncologist.
Background Patients with advanced esophageal cancer carry poor prognoses; limited data exist to guide second-line therapy in the metastatic setting. Paclitaxel has been used yet is associated with limited efficacy. There is preclinical evidence of sy
Publikováno v:
Abdominal Radiology. 47:2244-2253
Autor:
Rao Watson, Sam J. Lubner, Perry J. Pickhardt, Shane A. Wells, Will G Larison, Timothy J. Ziemlewicz, Meghan G. Lubner
Publikováno v:
Abdominal Radiology. 47:2647-2657
To evaluate the efficacy of percutaneous biopsy for diagnosing intrahepatic cholangiocarcinoma (IHCCA). Retrospective review of biopsy and pathology databases from 2006 to 2019 yielded 112 patients (54F/58 M; mean age, 62.9 years; 27 cirrhotic) with
Autor:
John F. Swietlik, Sam J. Lubner, Sharon M. Weber, Noelle K. LoConte, Daniel Mulkerin, Emily A. Knott, Daniel E. Abbott, J. Louis Hinshaw, Annie M. Zlevor, Marci L. Alexander, Colin Longhurst, Dustin A. Deming, Timothy J. Ziemlewicz, Paul F. Laeseke, Meghan G. Lubner, Fred T. Lee, Shane A. Wells, Allison B. Couillard, Nataliya Uboha
Publikováno v:
J Gastrointest Oncol
BACKGROUND: The purpose of this study is to evaluate the safety and intermediate-term efficacy of percutaneous microwave (MW) ablation for the treatment of colorectal liver metastases (CRLM) at a single institution. METHODS: A retrospective review wa
Autor:
Scott Kopetz, Emil Lou, Veena Shankaran, Emily K. Bergsland, S. Yousuf Zafar, Cathy Eng, Alok A. Khorana, Shaalan Beg, Sam J. Lubner, Leonard B. Saltz
Publikováno v:
JCO Oncology Practice. 16:383-388
Autor:
Liewen Jiang, Do Youn Oh, Rachna T. Shroff, Christina X. Chamberlain, John Bridgewater, Ghassan K. Abou-Alfa, William P. Harris, Milind Javle, Jorge Adeva, Juan W. Valle, Shuchi Sumant Pandya, Mitesh J. Borad, James M. Cleary, Bin Wu, Robin Kate Kelley, Sam J. Lubner, Maeve A. Lowery, Jonathan R. Whisenant, Daniel V.T. Catenacci, Lipika Goyal, Bin Fan, Teresa Macarulla, Adrian Murphy, Camelia Gliser, Andrew X. Zhu, Anthony B. El-Khoueiry
Publikováno v:
The Lancet. Oncology, vol 21, iss 6
BackgroundIsocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess th
Autor:
Dustin A. Deming, Noelle K. LoConte, Sam J. Lubner, Daniel Mulkerin, Jens C. Eickhoff, Nataliya Volodymyrivna Uboha
Publikováno v:
Investigational New Drugs. 38:1520-1525
Neuroendocrine tumors (NETs) are understudied and have limited systemic treatment options. Prior studies for patients with advanced NETs have demonstrated promising results when antimetabolite agents, including fluoropyrimidines, were combined with t